CliniGA CRO
Regulatory Affairs

Clinical trial regulatory and ethics support in Türkiye

Dossier preparation, authority and ethics committee planning, amendment lifecycle management and data protection-aware documentation for sponsors running studies with Turkish sites.

Illustrative photograph. Photo: EU2016 NL from The Netherlands · License: CC BY 2.0 · Cropped and resized.
Advancing Research. Transforming Healthcare.

Illustrative study workflow

Clinical research

Regulatory support across the study lifecycle

Regulatory work in Türkiye is document-intensive and unforgiving of inconsistency. Our approach is to treat the submission as one internally coherent package and to keep the same discipline through amendments, safety reporting and close-out.

Submission dossier preparation

Assembly and internal quality control of the clinical trial application package, with a version matrix tying every document to a protocol version.

Authority and ethics planning

Planning for review by the Turkish Medicines and Medical Devices Agency (TİTCK) and the relevant ethics committees, including query triage and controlled response handling.

Amendments and lifecycle maintenance

Substantial and non-substantial amendment handling, safety reporting obligations, and periodic reporting tracked consistently across all participating sites.

Import and supply documentation

Documentation support for investigational product import, release and accountability, coordinated with the sponsor's supply chain and depot partners.

KVKK and GDPR-aware data handling

Support in defining lawful basis, pseudonymisation, transfer mechanisms and retention for study data — aligned with both Turkish data protection law and GDPR where applicable.

Inspection and audit readiness

Regulatory document organisation, TMF completeness checks and preparation support for sponsor audits and authority inspections.

Türkiye alongside European programmes

For multi-country programmes, we harmonise the master protocol, investigator brochure and subject-facing documents first, then localise. In the EU, trials of medicinal products fall under Regulation (EU) No 536/2014 with a centralised application process; Türkiye's national process runs separately and on its own timeline.

Planning both tracks against one document baseline reduces amendment churn and keeps the sponsor's oversight documentation consistent across regions.

This page is general information. Regulatory requirements, formats and timelines change; sponsors should verify current requirements with the competent authority and relevant ethics committees before finalising a submission strategy.

Frequently asked questions

Who regulates clinical trials in Türkiye?
Clinical research on medicinal products is regulated nationally by the Turkish Medicines and Medical Devices Agency (TİTCK), with ethics committee review conducted in parallel. Requirements and formats are published by the authority and change over time, so the current guidance should always be confirmed before submission.
Does an EU submission under Regulation 536/2014 cover Türkiye?
No. Türkiye is outside the EU clinical trials framework, so an application submitted through the EU system does not cover Turkish sites. Sponsors running both should plan two coordinated tracks from a harmonised master document set.
What most often delays a Turkish submission?
Internally inconsistent dossiers and late informed consent translation. Cross-document quality control before submission usually saves more time than any other single intervention.
Can CliniGA act as the sponsor's local representative?
Local representation arrangements depend on the sponsor's legal structure and the specific study. We scope this case by case and document the responsibilities contractually rather than assuming a standard model.

Need a regulatory plan for Turkish sites?

Send the protocol synopsis and target timeline. We respond with a submission approach, document checklist and the assumptions behind each milestone.